Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05513365 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Dutasteride in Combination With CAB vs CAB in SDC

Study acronym: DUCT
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 4, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv6
  2. Publications: details revised at 1 of 1 entryv5
  3. Enrollment target: 98 to 26
    • Eligibility criteria expanded, about 21 words
    • Study description expanded, about 11 words
    • Study arms: 2 to 1
    v4
  4. Start date changed from estimate of Sep 20, 2022 to Sep 27, 2022v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 2022 to Sep 20, 2022
    • Site details revised
    • Collaborators expanded, about 9 words
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase 2 clinical trial on the addition of dutasteride to combined androgen blockade (CAB) therapy in recurrent and/or metastatic (R/M) salivary duct carcinoma (SDC) patients. The study included two cohorts of patients: Cohort A, which comprises ADT-naïve patients, and Cohort B, which comprises ADT-resistant patients. Cohort A is closed for inclusion as of April 18, 2024.
Trial Details
NCT Number NCT05513365
Lead Sponsor Radboud University Medical Center
Collaborators: ZonMw: The Netherlands Organisation for Health Research and Development
Conditions
(from sponsor)		 Salivary Duct Carcinoma
Enrollment 26 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov